Boosting crinecerfont, Neurocrine draws from gamut of FDA support

In the USA, two New Drug Applications (NDA) for crinecerfont have been accepted by the US regulator, and will be considered under the Priority Review scheme.

Developed by Neurocrine Biosciences (Nasdaq: NBIX), crinecerfont is intended for the treatment of classic congenital adrenal hyperplasia (CAH), a genetic disorder that affects the adrenal glands.

If approved, crinecerfont would be the first new treatment for CAH in 70 years, offering a novel approach to this rare endocrine disorder.